MODEL VERDICT
PharmaCyte Biotech, Inc. (PMCB)
Relative Valuation•Peer multiples, competitive benchmarking & quality-adjusted fair value
PharmaCyte Biotech, Inc. is currently trading at a 12846.08% discount to its peer-implied fair value.
13 industry peers matched by industry sector due to narrow curated coverage
| Ticker | Company | Market Cap | P/E | EV/EBITDA |
|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Incorporated | $124.98B | 32.07x | 24.91x |
| REGN | Regeneron Pharmaceuticals, Inc. | $65.76B | 15.26x | 15.86x |
| ARGX | argenx SE | $54.9B | 45.2x | 47.56x |
| ALNY | Alnylam Pharmaceuticals, Inc. | $38.88B | 125.05x | 69.09x |
| RPRX | Royalty Pharma plc | $24.09B | 31.24x | 20.74x |
| BNTX | BioNTech SE | $23.07B | -17.75x | - |
| UTHR | United Therapeutics Corporation | $23.03B | 19.48x | 13.4x |
| INCY | Incyte Corporation | $22.73B | 17.75x | 13.72x |
| ASND | Ascendis Pharma A/S | $16.11B | -63.2x | - |
| GMAB | Genmab A/S | $16.04B | 16.96x | 14.94x |
| JAZZ | Jazz Pharmaceuticals plc | $14.43B | -39.39x | 24.09x |
| EXEL | Exelixis, Inc. | $13.91B | 19.7x | 15.09x |
1 valuation metric · peer-median based
| Multiple | Current | Peer Median | vs Peers | Implied Price |
|---|---|---|---|---|
| P/EPrice paid for current earnings. | 0.24x | 31.24x | Discount -99.23% | $99.65 |
How the model derives the final fair value from peer baselines and quality metrics
Opportunity: The stock is trading at a 99.23% discount to its quality-adjusted fair value of $99.65. To reach its estimated fair value, the stock would need to appreciate by 12841.56% from its current price of $0.77.
Quality metrics are broadly comparable to peers.
Quality adjustments are capped at ±15% (up to ±20% for financial services) to prevent runaway premiums. Based on trailing twelve months and multi-year CAGR data where available.
How current multiples rank vs 1 years of the stock’s own history
| Multiple | Current | Historical Median | Percentile | Status |
|---|---|---|---|---|
| P/E1 years of data | 0.24x | 0.39x | 0th | Below historical norm |
PharmaCyte Biotech, Inc. currently trades near the lowest valuation levels observed during the last 1 years.
Model-identified caveats to consider
PMCB has a limited relative valuation using industry peers; based mainly on P/E, it looks cheap versus peers.
Answers to common questions about PMCB's relative valuation and our methodology.
PharmaCyte Biotech, Inc.'s fair value of $99.65 is the price at which the stock would trade if valued at the same multiples as its 13-company peer group, adjusted for differences in business quality. At $0.77, the stock trades at a +12841.56% discount to fair value. This is a reference point, not a price target.
Peers were grouped by industry classification and market capitalization. The 13 companies shown are the closest comparable names with clean, usable financial data.
PharmaCyte Biotech, Inc. has strengths in net debt / ebitda, and challenges in roic relative to its peer group. The Quality Adjustment section breaks down each driver.
No. This page provides an automated quantitative comparison of PharmaCyte Biotech, Inc. against its peers. It is not investment advice, a recommendation, or a solicitation. Valuation is only one factor in an investment decision — it does not account for growth catalysts, management quality, regulatory risk, or your personal financial situation.
A 12841.56% discount is substantial. Large discounts may signal that the market is overlooking value, but they can also reflect genuine business challenges or structural headwinds. Review the Risk Factors and Historical Context sections to assess whether the gap is justified.
Valuation data is refreshed weekly based on the latest financial filings, market prices, and analyst estimates. PharmaCyte Biotech, Inc.'s fair value, peer multiples, and quality scores will shift over time as new earnings are reported and stock prices change.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. Fair value estimates are model outputs under stated assumptions and should not be relied upon as the sole basis for any investment decision.